Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Sep 9;28(3):455-464.e2.
doi: 10.1016/j.chom.2020.07.005. Epub 2020 Jul 18.

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients

Nan Wang  1 , Yan Zhan  2 , Linyu Zhu  3 , Zhibing Hou  4 , Feng Liu  5 , Pinhong Song  5 , Feng Qiu  5 , Xiaolin Wang  6 , Xiafei Zou  6 , Deyun Wan  7 , Xiaosong Qian  7 , Shanshan Wang  8 , Yabi Guo  8 , Hao Yu  8 , Miao Cui  9 , Gangling Tong  10 , Yunsheng Xu  11 , Zhihua Zheng  12 , Yingying Lu  13 , Peng Hong  14
Affiliations
Observational Study

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients

Nan Wang et al. Cell Host Microbe. .

Abstract

Interferons (IFNs) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, a recent report of ACE2, the host factor mediating SARS-Cov-2 infection, identifying it as interferon-stimulated raised considerable safety concern. To examine the association between the use and timing of IFN-α2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study of 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (≤5 days after admission) of IFN-α2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-α2b, whereas late administration of IFN-α2b was associated with increased mortality. Among survivors, early IFN-α2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-α2b was associated with delayed recovery. Additionally, early IFN-α2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. We concluded that administration of IFN-α2b during the early stage of COVID-19 could induce favorable clinical responses.

Keywords: RNA virus; anti-retroviral agents; anti-viral immunity; cytokine storm syndrome; infectious disease; respiratory medicine; viral infection.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Sampling Strategy of COVID-19 Patient Records
Figure 2
Figure 2
Early IFN Therapy Associated with Reduced In-Hospital Mortality but not with Early Recovery of COVID-19 (A) Bar graph depicting initiation timing of IFN therapy among analyzed patients. Initiation of IFN therapy within first 5 days of hospitalization was empirically deemed early. (B) Kaplan-Meier curve of in-hospital mortality in patients stratified by IFN therapy status (Log-rank test of all curves, p < 0.001). (C and D) Cumulative event curves of hospital discharge (Log-rank test of all curves, p = 0.018) (C) and CT scan improvement (Log-rank test of all curves, p = 0.003) (D).
Figure 3
Figure 3
IFN-Based Therapies Associated with More Favorable Clinical Response than LPV/r in COVID-19 (A and B) Cumulative event curves of hospital discharge (Log-rank test of all curves, p < 0.001) (A) and CT scan improvement (Log-rank test of all curves, p < 0.001) (B) in survivors, excluding those that received late IFN therapy stratified by treatments. (C and D) Cumulative event curves of hospital discharge (Log-rank test, p < 0.001) (C) and CT scan improvement (Log-rank test, p < 0.001) (D) in survivors, excluding those that received late IFN therapy stratified by LPV/r use. (E) Kaplan-Meier curves of in-hospital mortality in all patients, excluding those that received late IFN therapy stratified by treatments (Log-rank test of all curves, p = 0.011).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Acharya D., Liu G., Gack M.U. Dysregulation of type I interferon responses in COVID-19. Nat. Rev. Immunol. 2020;20:397–398. - PMC - PubMed
    1. Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., Møller R., Jordan T.X., Oishi K., Panis M., Sachs D. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036–1045.e9, e1039. - PMC - PubMed
    1. Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K., Perlman S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19:181–193. - PMC - PubMed
    1. Channappanavar R., Fehr A.R., Zheng J., Wohlford-Lenane C., Abrahante J.E., Mack M., Sompallae R., McCray P.B., Jr., Meyerholz D.K., Perlman S. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Invest. 2019;129:3625–3639. - PMC - PubMed
    1. National Health Commission of the People’s Republic of China; 2020. Chinese management guideline for COVID-19 (version 7)http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb19... [in Chinese] - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources